Volume 1.21 | Jun 8

Hematopoiesis News 1.21, June 8, 2010.  
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


UF Oncologists Fight Leukemia with Two-Pronged Therapy, Clinical Trials to Start Within Months
A new therapy mounts a double-barreled attack on leukemia, targeting not just the cancer cells but also the environment in which those cells live and grow, researchers report. [University of Florida Press Release]

MethoCult® Express Video  
Learn about the benefits of MethoCult® Express
for cord blood samples

by STEMCELL Technologies


Stroke Prevention Study in Children with Sickle Cell Anemia, Iron Overload Stopped Early
The National Heart, Lung, and Blood Institute has stopped a clinical trial evaluating a new approach to reduce the risk of recurrent stroke in children with sickle cell anemia and iron overload because of evidence that the new treatment was unlikely to prove better than the existing treatment. [National Heart, Lung, and Blood Institute Press Release]

Maintenance Treatment With Oral Lenalidomide After Stem Cell Transplant Reduces Risk of Disease Progression for Multiple Myeloma Patients
The study evaluated the benefits of maintenance treatment with lenalidomide (Revlimid®) administered orally following an autologous stem cell transplant for patients with newly diagnosed multiple myeloma, compared to placebo. [Press release from Medical News Today discussing research presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO’s)]

SPRYCEL® (Dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to Gleevec® in Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. announced Phase III study results in which SPRYCEL (dasatinib) 100 mg once daily demonstrated a superior rate of confirmed complete cytogenetic response compared to Gleevec® (imatinib mesylate). [Press release from Bristol-Myers Company discussing online prepublication in the New England Journal of Medicine]

Request A Sample  
Column-Free Isolation of
Hematopoietic Stem and Progenitor Cells
with EasySep®

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)


Aberrant Induction of LMO2 by the E2A-HLF Chimeric Transcription Factor and its Implication in Leukemogenesis of B Precursor ALL with t(17;19)
Research demonstrates that cell lines and a primary sample of t(17;19)-acute lymphoblastic leukemia (ALL) expressed LMO2 at significantly higher levels than other B precursor ALLs did. [Blood]

The Human Stem Cell Hierarchy is Defined by a Functional Dependence on Mcl-1 for Self-Renewal Capacity
Researchers report a role for the Bcl-2 family member myeloid cell leukemia-1 (Mcl-1) as an indispensable regulator of self-renewal in human stem cells, and show that a functional dependence on Mcl-1 defines the human stem cell hierarchy. [Blood]

BCR and BCR-ABL Regulation During Myeloid Differentiation in Healthy Donors and in Chronic Phase/Blast Crisis CML Patients
Here researchers focused on the gene expression control of BCR and BCR-ABL upon myeloid differentiation in healthy donors, chronic phase and blast crisis patients. [Leukemia]

Wnt3a Activates Dormant C-Kit-Bone Marrow Derived Cells with Short-Term Multilineage Hematopoietic Reconstitution Capacity
The study reveals that Wnt3a activates unique cell fate decisions of dormant c-kit- that promotes short-term multilineage reconstitution capacity in vivo, thereby revealing a unique role for Wnt activation in hematopoiesis. [Stem Cells]

Taspase1 Functions as a Non-Oncogene Addiction Protease that Coordinates Cancer Cell Proliferation and Apoptosis
Taspase1, the mixed lineage leukemia and TFIIAalpha-beta cleaving protease, enables cell proliferation and permits oncogenic initiation. Here, researchers show its critical role in cancer maintenance and thus offer a new anticancer target. [Cancer Res]

Inhibition of c-MET is a Potential Therapeutic Strategy for Treatment of Diffuse Large B Cell Lymphoma
In this study, researchers first investigated the role of c-Met in a large series of diffuse large B cell lymphoma tissues in a tissue microarray format. [Lab Invest]


Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Dasatinib, administered once daily, as compared with imatinib, administered once daily, induced significantly higher and faster rates of complete cytogenetic response and major molecular response. [N Engl J Med]

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Nilotinib at a dose of either 300 mg or 400 mg twice daily was superior to imatinib in patients with newly diagnosed chronic-phase Philadelphia chromosome-positive chronic myeloid leukemia. [N Engl J Med]

Phase II Window Study on Rituximab in Newly Diagnosed Pediatric Mature B Cell Non-Hodgkin’s Lymphoma and Burkitt Leukemia
Researchers conducted a Phase II window study to examine activity and tolerability of rituximab in newly diagnosed pediatric B cell non-Hodgkin’s lymphoma. [J Clin Oncol]

Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study
Researchers investigated the efficacy of thalidomide added to melphalan and prednisone (MP-T) in a randomized Phase III trial. The objective of this study was to investigate the efficacy, toxicity, and effects on quality of life of MP-T. [J Clin Oncol]


The Leukemia & Lymphoma Society® and Onconova Therapeutics, Inc. Enter Partnership to Advance Clinical Development of ESTYBON™ in High Risk Myelodysplastic Syndrome Patients
The Leukemia & Lymphoma Society® and Onconova Therapeutics, Inc., announced that they are collaborating to support the clinical advancement of ESTYBON(TM) (ON 01910.Na), the lead compound under development for treating patients with high-risk myelodysplastic syndrome. [Onconova Therapeutics, Inc. Press Release]

Immucor Expects 2011 Net Income, Revenue Growth
Immucor Inc., which makes automated systems used in blood transfusions, said it expects net income and revenue growth in fiscal 2011. [Yahoo! Finance]

Costa Rica Puts Brakes on Popular Stem Cell Tourism
Costa Rica is cracking down on an unauthorized stem cell clinic that has attracted hundreds of foreigners seeking relief from degenerative diseases and serious injuries. [Reuters]

Grifols Agrees to Buy Talecris for $3.4 Billion
Grifols SA, Europe’s largest maker of blood-plasma products, agreed to buy Talecris Biotherapeutics Holdings Corp. for about $3.4 billion in cash and stock to expand its share to about a third of the U.S. market. [Bloomberg Businessweek]

Oklahoma Blood Institute to Open New Building
The Oklahoma Blood Institute’s new $10 million building is just south of the current location. Designed for donor comfort, the 47,000-square-foot structure features a landscaped plaza, open floor plan and new areas for giving marrow or blood stem cells. [Oklahoman]


STAR METRICS: New Way to Measure the Impact of Federally Funded Research
A new initiative–Science and Technology for America’s Reinvestment: Measuring the Effect of Research on Innovation, Competitiveness and Science, or STAR METRICS–promises to monitor the impact of federal science investments on employment, knowledge generation, and health outcomes. [National Institutes of Health, United States]

Administrative Supplements to Increase Public Awareness of Pediatric Cancers and Available Treatments and Research (NOT-CA-10-026) [National Institutes of Health, United States]

Market Withdrawal of GAMMAGARDLIQUID, Immune Globulin Intravenous (Human)  This voluntary market withdrawal is being conducted as a precautionary measure due to an increased number of adverse event reports of allergic reactions. [Food and Drug Administration, United States]

FDA Announces Collaboration with Drugs.com
The U.S. Food and Drug Administration announced that it will collaborate with the web site Drugs.com to expand access to the FDA’s consumer health information. [Food and Drug Administration, United States]

2010 Biological License Application Approvals
[Food and Drug Administration, United States]

2010 Biological Device Application Approvals [Food and Drug Administration, United States]

Emerging Infectious Diseases: Evaluation to Implementation for Transfusion and Transplantation Safety Public Workshop (Update) [Food and Drug Administration, United States]


International Society for Stem Cell Research (ISSCR) 8th Annual Meeting
June 16-19, 2010
San Francisco, United States

XXXIst International Congress of the International Society of Blood Transfusion (ISBT) in joint cooperation with the 43rd Congress of the German Society for Transfusion Medicine and Immunohematology (DGTI)
June 26-July 1, 2010
Berlin, Germany

Translational Cancer Medicine 2010 – USA
July 11-14, 2010
San Francisco, United States

United Kingdom National Stem Cell Network (UKNSCN) Annual Scientific Conference
July 12-14, 2010
Nottingham, United Kingdom

Select Biosciences 3rd Annual Stem Cells Europe Conference
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences 2nd Annual World Biobanking Summit
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences Inaugural Cellular Therapy Summit
August 24-25, 2010
Edinburgh, Scotland

The European Molecular Biology Organization (EMBO) Meeting 2010
September 4-7, 2010
Barcelona, Spain

International Society for Cellular Therapy (ISCT) – Europe 2nd Regional Meeting
September 11-14, 2010
Belgirate, Italy

Stem Cells USA & Regenerative Medicine Congress 2010
September 13-15, 2010
Philadelphia, United States

Society for Hematology and Stem Cells (ISEH) 2010 Meeting
September 15-18, 2010
Melbourne, Australia

Stem Cells and Regeneration
October 3-9, 2010
Woods Hole, United States

American Association of Blood Banks (AABB) Annual Meeting 2010
October 9-12, 2010
Baltimore, United States

Fraunhofer Life Science Symposium Leipzig 2010
October 29-30, 2010
Leipzig, Germany

52nd American Society of Hematology (ASH) Annual Meeting and Exposition
December 4-7, 2010
Orlando, United States

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Senior Scientist – Magnetic Cell Separation (STEMCELL Technologies)

Business Development Manager Europe – Cell Therapy Products (Pall Corporation)

Sr. Product Support and Training Specialist (CardianBCT)

Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here to post your career opportunities.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Hematopoiesis News: Archives  |  Events  |  Subscribe  |  Contact Us